Lisata Therapeutics terminates merger with Kuva Labs; Kuva failed to secure financing

LISATA THERAPEUTICS, INC.

Merger agreement terminated after Kuva Labs failed to obtain financing to fund tender offer.
Kuva must pay Lisata a $2M termination fee under the agreement.
Lisata reserves rights to seek damages for willful breach; no assurance of recovery.
Board to assess strategic alternatives including reverse merger, business combination, asset sales, or dissolution.
No timetable set for strategic review; no assurance of any transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.